Skip to main content

Advertisement

SpringerLink
Log in

Critical influenza and prophylactic antifungal therapy for aspergillosis: a nuanced approach to a pertinent infectious disease

  • Correspondence
  • Published:
Intensive Care Medicine Aims and scope Submit manuscript

A Correspondence to this article was published on 10 August 2021

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Coste A, De Longeaux K, Aubron C (2021) Influenza and prophylactic antifungal therapy for aspergillosis: addressing some questions first. Intensive Care Med. https://doi.org/10.1007/s00134-021-06488-x

    Article  PubMed  Google Scholar 

  2. Vanderbeke L, Janssen NAF, Bergmans DCJJ et al (2021) Posaconazole for prevention of invasive pulmonary aspergillosis in critically ill influenza patients (POSA-FLU): a randomised, open-label, proof-of-concept trial. Intensive Care Med 47:674–686. https://doi.org/10.1007/s00134-021-06431-0

    Article  CAS  PubMed  Google Scholar 

  3. Blot SI, Taccone FS, Van den Abeele AM et al (2012) A clinical algorithm to diagnose invasive pulmonary aspergillosis in critically ill patients. Am J Respir Crit Care Med 186:56–64. https://doi.org/10.1164/rccm.201111-1978OC

    Article  PubMed  Google Scholar 

  4. Meersseman W, Lagrou K, Maertens J et al (2008) Galactomannan in bronchoalveolar lavage fluid: a tool for diagnosing aspergillosis in intensive care unit patients. Am J Respir Crit Care Med 177:27–34. https://doi.org/10.1164/rccm.200704-606OC

    Article  PubMed  Google Scholar 

  5. Rijnders BJA, Schauwvlieghe AFAD, Wauters J (2020) Influenza-associated pulmonary aspergillosis: a local or global lethal combination? Clin Infect Dis 71:1764–1767. https://doi.org/10.1093/cid/ciaa010

    Article  PubMed  PubMed Central  Google Scholar 

  6. Verweij PE, Rijnders BJA, Brüggeman RJM et al (2020) Review of influenza-associated pulmonary aspergillosis in ICU patients and proposal for a case definition: an expert opinion. Intensive Care Med 46:1524–1535. https://doi.org/10.1007/s00134-020-06091-6

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Funding

LV is supported by an PhD fellowship of the Research Foundation – Flanders (FWO; grant number 11E9819N) and JW is supported by a FWO Fundamental Clinical Mandate (1833317N). We acknowledge support via IOF (Industrial research fund, KU Leuven) (3M180282) to JW, and via Merck Sharp & Dohme Belgium for the original POSA-FLU study (study medication and restricted grant for study organization).

Author information

Authors and Affiliations

  1. Department of Microbiology, Immunology and Transplantation, KU Leuven, Leuven, Belgium

    Lore Vanderbeke, Katrien Lagrou & Joost Wauters

  2. Medical Intensive Care Unit, University Hospitals Leuven, Leuven, Belgium

    Lore Vanderbeke & Joost Wauters

  3. Department of Laboratory Medicine and National Reference Center for Mycosis, University Hospitals Leuven, Leuven, Belgium

    Katrien Lagrou

  4. Radboudumc-CWZ Center of Expertise for Mycology, Radboudumc Center for Infectious Diseases (RCI), Nijmegen, The Netherlands

    Paul E. Verweij

  5. Department of Medical Microbiology, Radboud University Medical Center, Nijmegen, The Netherlands

    Paul E. Verweij

Authors
  1. Lore Vanderbeke
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Katrien Lagrou
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Paul E. Verweij
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Joost Wauters
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Lore Vanderbeke.

Ethics declarations

Conflicts of interest

LV reports non-financial support from Gilead Sciences, outside the submitted work. KL received consultancy fees from MSD, SMB Laboratoires Brussels and Gilead, non-financial support from Pfizer and MSD, received speaker fees from Gilead Sciences, FUJIFILM WAKO and Pfizer and a grant from Thermo Fisher Scientific. PEV reports grants from Mundipharma, grants from F2G, grants from Pfizer, grants from Thermofisher, grants from Gilead Sciences, non-financial support from IMMY, grants from Cidara, outside the submitted work. JW received speakers fee from MSD, Pfizer and Gilead, consultancy fee from Gilead and he obtained investigator-initiated grants from Gilead, Pfizer and MSD.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Vanderbeke, L., Lagrou, K., Verweij, P.E. et al. Critical influenza and prophylactic antifungal therapy for aspergillosis: a nuanced approach to a pertinent infectious disease. Intensive Care Med 47, 1343–1344 (2021). https://doi.org/10.1007/s00134-021-06532-w

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00134-021-06532-w

Search

Navigation